BioTalentum Ltd.

Admescope is a contract research organisation (CRO) providing the pharmaceutical, biotechnology and veterinary industry with premium quality tailor-made services to drug discovery in the area of ADME-Tox.

The service offering is widely spread, from highly tailored and optimised studies to high-throughput screening. Admescope’s unique expertise lies in in vitro & in vivo drug metabolism; including metabolite profiling & identification, drug-drug interactions and quantitative bioanalysis. The right level of research can always be found for the customer whether in the discovery or lead optimisation phase.

All of the services include comprehensive study consulting which enables tailoring the study according to customers’ specific needs. The state-of-art quality data is ensured by optimising the conditions according to the compounds instead of using generic protocols. All of the data can be interpreted for the customer and helped to understand the real meaning of the numerical values and observations.

Service Offering

• in vitro Metabolism
• in vivo DMPK
• Drug Interactions
• Quantitative Bioanalysis
• Permeability & Transporters
• Physicochemistry & Binding
• in vitro Toxicology
• Biologics

AGINKO Research is the premiere CRO for preclinical work in osteoarticular pathologies. We offer a wide range of contract research services to support Drug and Medical Device established companies as well as start-ups and academia. From industry standard protocols to customized research design, our animal models and assays, both on an in vivo or in vitro basis, provide key tools for compound discovery and product development.

Given our expertise, know-how, and network in the field of osteoarticular pathologies, AGINKO today also offers a full range of histology services for your preclinical and clinical trials as well as general consulting services (e.g., regulatory, strategy, financing) devoted to osteoarticular pathologies.


#Osteoarticular #CRO #Cartilage #Repair #Arthritis #Fracture #Osteoporosis #Preclinical #Pain #Disc #Spine #Infection

Cyprotex is the world's largest contract research organisation specialising in preclinical ADME Tox. Cyprotex provides the most complete range of ADME Tox CRO services available anywhere:

* High Throughput ADME screening
* Customised ADME assays
* In silico ADME predictive modeling
* In vitro toxicology

Accelerō® Bioanalytics GmbH is a certified GLP test facility, and operates in compliance with ICH GCP regulations. Competent authorities approved Accelero´s Biosafety Level S2 laboratories for both microbiology and genetic engineering.

Accelero is proud to serve our clients with:

• OECD GLP approved facilities for analytical, non-clinical studies.
• ICH E6 R1 GCP compliant analytical facility for clinical phase 0 to 3 studies.
• Facility approved for handling and cultivation of BSL-2 micro-organisms (bacteria, yeasts).
• Facility approved for genetic engineering / cloning / analysis of safety level S2 GMOs
(bacteria, yeasts, viruses, plants, animals).
• Approval for the import and analysis of animal by-products from non-EU countries (e.g. like U.S.A., China).

Accelero services include, but are not limited to:

• Pharmacokinetic / toxicokinetic characterization (ELISA, qPCR, immuno qPCR).
• Biodistribution and shedding (qPCR).
• Biomarker screening on the RNA level (qPCR, microarray) and the protein level (microarray).
• Cell-based in vitro immunoassays (ELISA, EliSpot, flow cytometry).
• Particle-based multiplex immunoassays (flow cytometry).
• Particle-based multiplex miRNA (microRNA) assays (flow cytometry).
• Cell proliferation and cytotoxicity assays (flow cytometry, EliSpot).
• Gene expression assays (RTqPCR).
• GLP training services (basic courses, in-house trainings).
• Antibody detection assays (ADA): screening, confirmatory, neutralization (EliSPOT).
• Preclinical consulting services with regards to GLP and bioanalysis.
• Complement activation monitoring.
• Supply chain services e.g. like sample transport and shipping organisation, preparation of clinical kits.

All analytical methods are developed and validated according to the respective EMA, FDA, and/or ICH guidelines.

Accelero® is a trademark fully owned by Accelero Bioanalytics GmbH, Berlin (Germany).

Last update of this page: 31-DEC-2017 by CL

ADC Biotechnology Ltd was founded in 2010 to develop and commercialise next generation conjugation technologies to the Antibody Drug Conjugate market. Bioconjugation using our proprietary 'Lock-Release'​ technology involves conjugation of proteins that are immobilised on solid supports, which delivers a number of key product advantages from minimal aggregate formation to minimal residual free drug and enhanced yields. From basic R&D applications through to improved supply economics and product risk management application of our 'Lock-Release'​ platform drives value through better products delivered with greater efficiency.

In addition to technology development, ADC Biotechnology offers a range of technical services, including conjugation (conventional and Lock-Release) to a variety of toxin payloads, toxin-linker design and synthesis and supply of ADCs for proof of concept and toxicology testing.

For more information on our services and Lock Release please visit

www.adcbio.com